Navigation Links
Regenesis Biomedical Announces Additions to Board of Directors

Strengthens breadth of experience and business expertise

SCOTTSDALE, Ariz., Aug. 22 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant(R) Wound Therapy System, announced today the addition of two members to its Board of Directors. The two new directors are Peter G. Savas, Chairman and CEO of Alseres Pharmaceuticals, and Charles "Chuck" S. Lunden, a principal with Bederson and Company.


Peter Savas serves as Chairman and Chief Executive Officer of Alseres Pharmaceuticals. Prior to joining Alseres, Peter was Chairman and Chief Executive Officer of Aderis Pharmaceuticals, where he completed a $45 million private placement, strengthened the Board of Directors, Scientific Advisory Board and management team and rationalized the company's new product development partnerships. Peter holds his Bachelor of Arts degree in chemistry from Syracuse University.

Chuck Lunden is a Principal with Bederson and Company, certified public accountant consultants who provide financial and accounting services. He has comprehensive experience in corporate valuation and financial, tax and corporate management services. His designations include Certified Public Accountant, Accredited in Business Valuations, Certified Fraud Examiner, Certified Management Accountant, Chartered Life Underwriter, and Fellow of the Life Management Institute. Chuck holds a Bachelor of Science degree in economics from the University of Pennsylvania's Wharton School of Business. He is a member of the Board of Directors of HealthCare Data Diagnostics, a Medicare data analysis firm specializing in fraud detection. He is also a Member of the Board of Directors of the Spanish Health Ministries Inc.

"We are pleased to welcome these outstanding individuals to our team," said Virginia Rybski, Acting President of Regenesis. "Regenesis continues to demonstrate impressive revenue growth, and the perspectives of these individuals will contribute to our ongoing business plan execution."

About the Provant Wound Therapy System

Provant uses pulsed-radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative superficial soft tissues.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

Contact: Regenesis Biomedical, Inc.

Scott Robey, Vice President Marketing 480-970-4970

SOURCE Regenesis Biomedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
2. Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts
3. Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R)
4. Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
5. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
6. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
7. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
8. Roche and Response Biomedical Corporation Aim to Reduce Vein-to-Brain Time with New Point-of-Care Cardiac Tests
9. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
10. HIPAA Privacy Rule Impedes Biomedical Research
11. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
Post Your Comments:
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
(Date:11/24/2015)... VANCOUVER , Nov. 24, 2015 /CNW/ - iCo ... ICOTF), today reported financial results for the quarter ... are expressed in Canadian dollars and presented under ... the United States ," said Andrew ... "These advancements regarding iCo-008 are not only value ...
(Date:11/24/2015)... Global, Inc., a worldwide provider of clinical research services headquartered in ... company has set a new quarterly earnings record in Q3 of ... for Q3 of 2014 to Q3 of 2015.   ... with the establishment of an Asia-Pacific office ... Kingdom and Mexico , with the ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... Chief Financial Officer, will participate in the Piper Jaffray 27 th ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. EST ...
Breaking Biology Technology:
(Date:10/27/2015)... 2015 In the present market scenario, security ... various industry verticals such as banking, healthcare, defense, electronic ... demand for secure & simplified access control and growing ... hacking of bank accounts, misuse of users, , and ... PC,s, laptops, and smartphones are expected to provide potential ...
(Date:10/26/2015)... ALTO, Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern ... Alliance , today announced the launch of its latest ... first unified platform enabling organizations to use standards-based authentication ... The Nok Nok S3 Authentication Suite is ideal for ...
(Date:10/22/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics software ... September 30, 2015.  --> --> ... a decrease of 33% compared to $6.0 million in the same ... was $2.2 million, or $0.10 per diluted share, which compared to ... a year ago.  --> --> ...
Breaking Biology News(10 mins):